

An Expanded Access Program for the non-invasive detection of clear cell renal cell carcinoma (ccRCC) in patients with renal masses utilizing 89Zirconium-labelled girentuximab (89Zr-DFO-girentuximab)

Status: Recruiting

Eligibility Criteria

Sex: Male or Female

Age Group: 18 years and over

This study is NOT accepting healthy volunteers

Inclusion Criteria:

- 18 to 99 years old - evidence of renal mass(es) obtained from conventional diagnostic imaging with CT or MRI - agree to practice highly effective contraception until a minimum of 42 days after receiving study drug

Exclusion Criteria:

- mass known to be a metastasis of another primary tumor - active non-renal cancer requiring therapy - women who are pregnant or breastfeeding

Conditions & Interventions

Interventions:

Diagnostic Test: 89Zr-DFO-girentuximab

Conditions:

Cancer

Keywords:

Clear Cell Renal Cell Carcinoma, Kidney Cancer

More Information

Description: This Expanded Access Program (EAP) will enable the use of 89Zr-DFO-girentuximab with PET/CT scans to detect clear cell renal cell carcinoma in patients with kidney masses. It aims to gather real-world safety and effectiveness data and understand how PET imaging affects patient management.

Study Contact: Lucas Brown - brow4398@umn.edu

Principal Investigator: Ian Okazaki

IRB Number: STUDY00024231

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact sfinder@umn.edu if you have questions or need assistance.